Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
Holding SGMO?
Track your performance easily
SGMO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.30 - $3.18
Previous Close$1.3
Volume10.91M
Average Volume (3M)9.92M
Market Cap
$271.24M
Enterprise Value$259.77M
Total Cash (Recent Filing)$39.20M
Total Debt (Recent Filing)$27.73M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Feb 19, 2025EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding208,646,870
10 Day Avg. Volume12,172,559
30 Day Avg. Volume9,924,830
Standard Deviation0.35
R-Squared0.04
Alpha-0.00230
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)7.11
Price to Sales (P/S)5.19
Price to Cash Flow (P/CF)5.80
P/FCF Ratio5.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.97
Enterprise Value/Gross Profit1.47
Enterprise Value/Ebitda-2.06
Forecast
1Y Price Target
$5.50Price Target Upside307.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Sangamo Biosciences News
Bulls Say, Bears Say
Bulls Say
Financial And Strategic GrowthSangamo has buffered cash risk with capsid deals with Roche ($50M) and Astellas ($20M), and sees potential for a third deal too.
Gene Therapy AdvancementsSangamo's emerging neurology-focused genetic medicines pipeline is generating optimism as it heads into key study starts and data releases.
Partnerships And CollaborationsSangamo's recent partnerships with Genentech and Astellas, along with advanced discussions for its Fabry program, are aimed at advancing its neurology pipeline programs.
Bears Say
Financial PerformanceSGMO's cash position can fund operations only into 1Q25, increasing the urgency to find a partner for its Fabry gene therapy program.
Market RisksSGMO is no longer eligible for $220MM in regulatory & first-sales milestones, increasing funding pressure.
Partnership And CollaborationPfizer's decision increases cash overhang risk for SGMO, because the company will no longer be eligible for ~$70M milestone payment for BLA filing.
---
Ownership Overview
2.86% Insiders
16.75% Mutual Funds
10.59% Other Institutional Investors
61.80% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMO FAQ
What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $0.30 and its highest was $3.18 in the past 12 months.
What is Sangamo Biosciences’s market cap?
Currently, no data Available
When is Sangamo Biosciences’s upcoming earnings report date?
Sangamo Biosciences’s upcoming earnings report date is Feb 19, 2025 which is in 43 days.
How were Sangamo Biosciences’s earnings last quarter?
Sangamo Biosciences released its earnings results on Nov 12, 2024. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.015 by $0.055.
Is Sangamo Biosciences overvalued?
According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
Does Sangamo Biosciences pay dividends?
Sangamo Biosciences does not currently pay dividends.
What is Sangamo Biosciences’s EPS estimate?
Sangamo Biosciences’s EPS estimate is -$0.09.
How many shares outstanding does Sangamo Biosciences have?
Sangamo Biosciences has 208,646,870 shares outstanding.
What happened to Sangamo Biosciences’s price movement after its last earnings report?
Sangamo Biosciences reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.015. Following the earnings report the stock price went down -9.963%.
Which hedge fund is a major shareholder of Sangamo Biosciences?
Among the largest hedge funds holding Sangamo Biosciences’s share is Graham Capital Management, L.P.. It holds Sangamo Biosciences’s shares valued at 135K.
---
Sangamo Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (307.41% Upside)
$5.50 (307.41% Upside)
Blogger Sentiment
Bullish
SGMO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 156.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 41.8%
Last 30 Days ▲ 57.8%
Last 30 Days ▲ 57.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
197.35%
12-Months-Change
Fundamentals
Return on Equity
-156.42%
Trailing 12-Months
Asset Growth
-49.36%
Trailing 12-Months
Company Description
Sangamo Biosciences
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
---
SGMO Company Deck
---
SGMO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was positive, highlighting significant regulatory and clinical advancements, as well as strategic partnerships, despite the financial constraints posed by a limited cash runway.Read More>---
SGMO Stock 12 Month Forecast
Average Price Target
$5.50
▲(307.41% Upside)
Technical Analysis
Best Analysts Covering SGMO
1 Year
1 Year Success Rate
9/19 ratings generated profit
1 Year Average Return
+28.38%
reiterated a buy rating 8 days ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +28.38% per trade.
---